Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
2.050
+0.140 (+7.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Atai Life Sciences N.V.
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
36 Stocks Moving In Wednesday's Mid-Day Session
December 15, 2021
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...
Via
Benzinga
Dow Down Triple Digits as Fed Meeting Wraps Up
December 15, 2021
Stocks have deepened their morning losses by midday, with the Dow Jones Industrial Average down 119 points, while both the Nasdaq Composite and S&P 500 Index are firmly in the red as well.
Via
Talk Markets
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates
December 15, 2021
Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S...
Via
Benzinga
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
December 13, 2021
Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
December 13, 2021
Photo by Raimond Klavins
Via
Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
December 12, 2021
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...
Via
Benzinga
Topics
Derivatives
Exposures
Derivatives
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
December 08, 2021
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics...
Via
Benzinga
Topics
Death
Exposures
Death
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
December 08, 2021
Photo by Michael Longmire on...
Via
Benzinga
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
December 07, 2021
Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent invest...
Via
Benzinga
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
December 01, 2021
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Analyst Ratings For ATAI Life Sciences
November 30, 2021
Over the past 3 months, 6 analysts have published their opinion on ATAI Life Sciences (NASDAQ:
Via
Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:
Via
Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
November 14, 2021
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.
Via
Talk Markets
70 Biggest Movers From Yesterday
November 16, 2021
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...
Via
Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Analyst Ratings For ATAI Life Sciences
November 11, 2021
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021
November 11, 2021
Upgrades Barrington Research upgraded the previous rating for Clear Channel Outdoor Holdings Inc (NYSE:
Via
Benzinga
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
November 09, 2021
Shares plunged, despite a psilocybin-based drug reducing depression in a trial.
Via
Investor's Business Daily
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
November 02, 2021
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug...
Via
Benzinga
ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study
November 01, 2021
ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated...
Via
Benzinga
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
October 24, 2021
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.
Via
Talk Markets
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
October 15, 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.
Via
Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
October 12, 2021
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.
Via
Talk Markets
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders
October 11, 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the...
Via
Benzinga
Atai Life Launches Depression-Focused Firm
October 11, 2021
Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. ...
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.